Hinweis zum Datenschutz bei Google Jetzt ansehen Ich möchte das später lesen

Anmelden

Patentsuche Englisch Französisch Stand der Technik suchen Über diesen Antrag diskutieren

Δ9 tetrahydrocannabinol (δ9 thc) solution metered dose inhalers and methods of use

WO 2000024362 A2

ZUSAMMENFASSUNG

The present invention provides therapeutic formulations for solutions of Δ9-tetrahydrocannabinol to be delivered by metered dose inhalers (100), (102). The formulations, which utilize non-CFC propellants, provide a stable aerosol-deliverable source of Δ9-tetrahydrocannabinol for the treatment of various medical conditions, such as nausea, and vomiting associated with chemotherapy; muscle spasticity; pain; anorexia associated with AIDS wasting syndrome; epilepsy; glaucoma; bronchial asthma; and mood disorders.

Veröffentlichungsnummer	WO2000024362 A2
Publikationstyp	Anmeldung
Anmeldenummer	PCT/US1999/024486
Veröffentlichungsdatum	4. Mai 2000
Eingetragen	20. Okt. 1999
Prioritätsdatum	27. Okt. 1998
Auch veröffentlicht unter	CA2344637A1, 12 weitere »
Erfinder	Joanne Peart, Peter Byron, Aron Lichtman, Billy Martin
Antragsteller	Virginia Commonwealth University
Zitat exportieren	BiBTeX, EndNote, RefMan

Patentzitate (3), Nichtpatentzitate (1), Referenziert von (19), Klassifizierungen (16), Juristische Ereignisse (17)

Externe Links: Patentscope, Espacenet

BESCHREIBUNG (OCR-Text kann Fehler enthalten)

Δ^9 TETRAHYDROCANNABINOL (Δ^9 THC) SOLUTION METERED DOSE INHALERS AND METHODS OF USE

DESCRIPTION

BACKGROUND OF THE INVENTION

Field of the Invention The invention is generally related to the therapeutic use of

ANSPRÜCHE (OCR-Text kann Fehler enthalten)

We claim: 1. An aerosol-dispensable pharmaceutical composition, comprising: a hydrofluoroalkane propellant; and Δ^9- tetrahydrocannabinol present in a pharmaceutically acceptable form and at a pharmaceutically effective concentration dissolved in said hydrofluoroalkane propellant.

2. The aerosol dispensable pharmaceutical composition of claim 1 wherein said

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

metered dose inhaler (MDI) for the aerosol administration of Δ^9 THC to patients suffering from nausea and vomiting associated with cancer chemotherapy, muscle spasticity, pain, anorexia associated with AIDS wasting syndrome, epilepsy, glaucoma, bronchial asthma, mood disorders, and the like.

Background Description "Medical Marijuana" is a timely and controversial subject that is currently receiving widespread public attention. While marijuana is usually thought of as an illegal "recreational" drug, it also has a long history as a medicine. In 1997, the National Institutes of Health (NIH) released a review of the scientific data concerning potential therapeutic uses for marijuana. In that review, the NIH found that marijuana may indeed have beneficial medicinal effects and recommended that researchers develop alternative dosage forms for the drug, such as a "smoke free" inhaled delivery system (1). Table 1 summarizes the findings of several studies (references 2-18) that have documented therapeutically beneficial medicinal uses of the major active component of marijuana, Δ^9 tetrahydrocannabinol (Δ^9 THC). TABLE 1. The Use of Δ^9THC for the Treatment of Assorted Clinical Conditions

Condition and Administration Findings Reference

Number of Route and Dose

Patients

AIDS-associated Oral placebo, 2.5 mg THC Long term THC Beal et al., anorexia and cachexia; once or twice daily treatment was well- 1997 94 patients; increasing to 20 mg daily tolerated; THC 12 months improved appetite and only tended to increase weight compared to controls

AIDS-associated Oral placebo or 2.5 mg 57% and 69% of vehicle Beal et al., anorexia and cachexia; THC twice daily and THC patients were 1995 139 patients; evaluable for efficacy. 42 days Appetite increased 38% over baseline for THC group compared to only 8% for the placebo group. THC also decreased nausea. No significant changes were found between the groups for weight change

without the use of a solubilizing agent selected from the group consisting of solvents and surfactants.

---

3. The aerosol-dispensable pharmaceutical composition of claim 1 wherein said hydrofluoroalkane is selected from the group consisting of: HFA 134a and HFA 227.

---

4. The aerosol-dispensable pharmaceutical composition of claim 3 wherein said hydrofluoroalkane is present in an amount in excess of 85% by weight.

---

5. The aerosol-dispensable pharmaceutical composition of claim 1 further comprising an organic solvent.

---

6. The aerosol-dispensable pharmaceutical composition of claim 5 wherein said organic solvent is ethanol present in an amount ranging up to 15% by weight.

---

7. The aerosol-dispensable pharmaceutical composition of claim 1 wherein said pharmaceutically effective concentration of Δ^9-tetrahydrocannabinol ranges from 0.05 to 10% by weight.

---

8. The aerosol-dispensable pharmaceutical composition of claim 1 wherein said pharmaceutically effective concentration of Δ^9-tetrahydrocannabinol ranges from 0.1 to 6% by weight.

---

9. The aerosol-dispensable pharmaceutical compositon of claim 1 wherein Δ^9-

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

Nausea and emesis due Oral THC, 15mg/m^2 Reduction in McCabe et al., to cancer chemotherapy-induced 1988 chemotherapy; nausea and vomiting in 36 patients who had 64% of patients given experienced severe THC compared to nausea and vomiting prochloperazine; side that was refractory to effects included prochlorperazine or dysphoria; authors thiethylperazine recommend initial THC dose of 5 m /πr

TABLE 1. The Use of Δ^{9}THC for the Treatment of Assorted Clinical Conditions

Nausea and emesis due to cancer chemotherapy; 53 patients which were refractory to other antiemetics	Oral 5 or 15 mg/m^2 THC four times per day	72% of patients exhibited a THC-induced partial or complete blockade of vomiting	Lucas and Laszlo, 1980
Nausea and emesis due to cancer chemotherapy; 84 patients	Oral 10 mg/m^2 THC of prochloperazine	THC more effective than prochloperazine	Sallan et al., 1980
Nausea and emesis due to cancer chemotherapy; 116 patients	Oral 15 mg THC, 10mg prochloperzine or placebo	Equal antiemetic effects between THC and prochlorperazine, effects of each greater than placebo; considerably more CNS side effects with THC than prochlorperazine	Frytak et al., 1979
Nausea and emesis due to cancer chemotherapy; 15 patients	Oral placebo or 10 mg/m^2 THC every 3 hours for a total of 5 doses, THC (17 mg) laced cigarettes of placebo were given if vomiting occurred	93% patients had a reduction in nausea and vomiting, 53% had an excellent response, 40% had a fair response; plasma THC levels 7.1±6.9 (mean ± SD) ng/ml. Side effects included sedation, tachycardia, few other side effects	Chang et al., 1979
Pain due to advanced cancer; 10 patients	Oral placebo and 5, 10, 15 or 20mg THC	Pain relief, elevated mood, appetite stimulation, drowsiness, slurred speech, mental clouding	Noyes, et al, 1975

10. A solvent free pharmaceutical composition consisting essentially of 1,1,1,2,3,3,3-hydrofluoropropane (HFA 227) and Δ^9- tetrahydrocarmabinol.

11. A solvent free pharmaceutical composition consisting essentially of 1,1,1 ,2-hydrofluroethane (HFA 134a) and Δ^9- tetrahydrocannabinol.

12. A method of treating a patient in need thereof with an aerosolized pharmaceutically acceptable form of Δ^9- tetrahydrocannabinol, comprising the step of: administering an aerosolized dose of a pharmaceutically acceptable form of Δ^9-tetrahydrocannabinol as respirable droplets to a patient's lung from a composition comprised of a hydrofluoroalkane propellant and said pharmaceutically acceptable form of Δ^9- tetrahydrocannabinol.

13. The method of claim 12 wherein said composition comprises a pharmaceutically acceptable solvent.

14. The method of claim 12 wherein said composition is solvent-free.

15. The method of claim 12 wherein said aerosolized dose is sufficient to reduce nausea.

16. The method of claim 12 wherein said aerosolized dose is sufficient to reduce vomiting.

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

TABLE 1. The Use of Δ⁹THC for the Treatment of Assorted Clinical Conditions			
Pain due to advanced cancer; 34 patients	Placebo, 10 and 20mg THC, and 60 and 120 codeine	THC produced a similar degree of analgesia, with greater potency than codeine. THC CNS side effects included sedation, mental clouding, ataxia, and disorientation	Noyes et al. 1975
Spasticity related to multiple schlerosis; 2 patients	Oral 10 or 15mg THC, rectal dose of 5 or 10mg THC	Improvement in passive mobility and walking ability	Brenneisen et al., 1996
Spasticity related to multiple schlerosis; 13 patients	Oral 2.5 to 15mg THC once or twice daily or placebo	Significant subjective improvement in spasticity at 7.5mg THC and higher, no significant improvement in objective measurements	Ungerleider et al., 1987
Spasticity related to multiple schlerosis; 8 patients, single blind	Oral 5 to 15mg THC	5 of 8 patients had mild subjective improvement in tremor. 2 of 8 patients had both objective and subjective improvement	Clifford, 1983
Spasticity related to multiple schlerosis; 9 patients	Placebo, or 5 or 10mg THC	Decrease in spasticity compared to placebo treatment, minimal side effects	Petro and Ellenberger, 1981
Spasticity and pain due to spinal cord injury; 1 patient	Oral placebo, THC (5 mg), or codeine (50 mg)	THC and codeine had analgesic effect compared to the placebo treatment. THC had a beneficial effect on spasticity whereas codeine did not	Maurer et al., 1990

17. The method of claim 12 wherein said aerosolized dose is sufficient to reduce pain.

18. The method of claim 12 wherein said aerosolized dose is sufficient to relieve muscle spasticity.

19. The method of claim 12 wherein said aerosolized dose is sufficient to relieve migraine headaches.

20. The method of claim 12 wherein said aerosolized dose is sufficient to relieve movement disorders.

21. The method of claim 12 wherein said aerosolized dose is sufficient to increase appetite in patients suffering from cachexia.

22. The method of claim 12 wherein said pharmaceutically acceptable form of Δ^9- tetrahydrocannabinol is pure Δ^9- tetrahydrocannabinol and said hydrofluoroalkane is selected from the group consisting of HFA 134a and HFA 227.

23. A metered dose inhaler, comprising, a housing; a metering valve connected to said housing; and, an aerosol-dispensable pharmaceutical composition which includes a hydrofluoroalkane propellant and Δ^9- tetrahydrocannabinol present in a pharmaceutically effective concentration dissolved in said hydrofluoroalkane propellant.

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

TABLE 1. The Use of Δ^9THC for the Treatment of Assorted Clinical Conditions			
Glaucoma, 6 patients	Oral placebo or 5, 10, 15 and 20 mg THC	Pain relief, elevated mood, appetite stimulation, drowsiness, slurred speech, mental clouding	Merritt et al, 1980
Ten subjects with normal intra ocular pressure	Intravenous THC (0.022 or 0.044 mg/kg)	Decreased intra ocular pressure by a mean of 37%	Cooler and Gregg, 1977
Nausea and emesis due to cancer chemotherapy; refractory to other antiemetics	Oral 10 mg/m^2 THC or placebo	In 20 courses of THC, 5 resulted in no vomiting, 9 resulted in a reduction of vomiting, 3 resulted in no decrease in vomiting, and 2 were unevaluable. THC was significantly better than placebo in decreasing vomiting.	Sallan et al., 1975

When marijuana is used illegally as a recreational psychoactive drug, the active ingredient Δ^9 THC is usually delivered to the lungs as an impure non-pharmaceutical aerosol in the form of marijuana smoke. Aerosolized Δ^9 THC in the inhaled smoke is absorbed within seconds and delivered to the brain efficiently. Table 2 and references 19-20 describe the pharmacokinetics of the administration of Δ^9 THC. As can be seen, inhalation is the preferred route of delivery for Δ^9 THC. When compared to oral delivery, inhalation provides a more rapid onset of pharmacological action and peak plasma levels. The effects achieved via inhalation are comparable to those achieved when the drug is administered intravenously, but inhalation is a much less invasive technique.

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

TABLE 2. Pharmacokinetics of Δ^9THC Given Orally, Intravenously or by Smoking

Route	Dose	% Dose in Plasma	Onset of Pharmacological Action	Peak Plasma Levels	References
Oral, sesame oil in gelatin capsules	2.5, 5, or 10 mg	10 to 20%	0.5 to 1 hour	120-480 min	(PDR, 1995)
Oral, in cookies	20 mg	4 to 12%	120-180 min	60-90 min	(Ohlsson, et al., 1980)
Intra venous, bolus	5 mg	100%	10 min	3 min	(Ohlsson, et al., 1980)
Smoking (THC lost to side stream smoke and pyrolysis	13 mg	8 to 24%	10 min	3 min	(Ohlsson, et al., 1980)

Currently, the sources of Δ^9 THC for patients who could benefit from the drug are very limited. An oral form of Δ^9 THC (MARINOL) is marketed as a treatment for nausea and vomiting related to cancer chemotherapy, and as an appetite stimulant in patients suffering from AIDS wasting syndrome. In MARINOL, pharmaceutical grade Δ^9 THC is dissolved in sesame oil, encapsulated in gelatin capsules and delivered orally. However, when the drug is taken orally, the absorption is slower and more variable than when inhaled, with an onset of action between 30 minutes and 2 hours (Table 2). Alternatively, some cancer patients do manage to obtain and smoke marijuana in order to alleviate such conditions as nausea and vomiting due to chemotherapy. This is, however, technically illegal and is thus obviously a less than ideal treatment protocol. There is no currently available pharmaceutically acceptable aerosol form of Δ^9 THC.

It would be advantageous to have available a form of pharmaceutical grade Δ^9 THC that could be administered as an aerosol. This would provide a means for rapid uptake of the drug without resorting to the illegal practice of smoking marijuana. Also, the potential adverse side effects encountered by smoking marijuana would be avoided. Further, an aerosol preparation of pharmaceutically pure Δ^9 THC could be administered in known, controlled dosages.

In 1976, Olsen et al. described a chlorofluorocarbon (CFC) propelled MDI formulation of Δ^9 THC (21). However, Δ^9 THC is

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

content in this formulation was so high (-23%) as to create an aerosol with droplets too large to be effectively inhaled (22). The Δ^9 THC CFC formulations were tested for use in treating asthma but were shown to be only moderately effective (23, 24). Moreover, CFC propellants have since been banned so that such a formulation is now useless. It would clearly be advantageous to develop a new aerosol formulation in which the Δ^9 THC is stable, the droplets are of a size that can be effectively inhaled, and which utilizes a non-CFC propellant.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a stable aerosol-dispensable pharmaceutical composition comprising a non-CFC propellant and a pharmaceutically effective concentration of Δ^9 THC. More particularly, it is an object of the present invention to provide a stable aerosol-dispensable pharmaceutical composition comprising a hydro fluoroaikane propellant, (for example, HFA 227 or HFA 134a) and Δ^9 THC. The propellant is present in the range of approximately 78 to 100% by weight, and more particularly the propellant is present in the range of approximately 85 to 100% by weight. An organic solvent such as ethanol can be used to assist in solubilizing the Δ^9 THC in the propellant but is not required. If a solvent is used, preferably less than 20%> by weight will be required, and most preferably less than 15% by weight will be required. The pharmaceutically effective concentration of Δ^9 THC is preferably in the range of 0.05 to 10% by weight, and most preferably in the range of 0.1 to 6% by weight. The pharmaceutical composition of the present invention can be used to treat a variety of medical conditions including nausea and vomiting associated with cancer chemotherapy, muscle spasticity, pain, anorexia associated with AIDS wasting syndrome, anorexia associated with cancer chemotherapy, epilepsy, glaucoma, bronchial asthma, mood disorders, migraine headaches.

DETAILED DESCRIPTION OF THE DRAWINGS

Figure 1. Δ^9 THC MDI characterization summary before and after storage at 40°C and 82% relative humidity (RH).

Figure 2. Generalized schematic drawings of a Δ^9 THC MDI.

DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT OF THE INVENTION

The instant invention provides a series of non-ozone depleting pressurized metered dose inhaler formulations of Δ^9 THC. In preferred embodiments of the invention, the formulations contain the pharmaceutically acceptable, non-ozone depleting hydro fluoroaikane propellants HFA 134a (1,1,1,2-tetrahydrofluoroethane) and HFA 227 (1,1,1,2,3,3,3-

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

When the propellant is a hydrofluoroalkane, it has been discovered that the propellant may be used with or without a solvent such as ethanol. Higher percentages of solvent generally allow higher levels of dissolution of Δ^9 THC. However, higher percentages of solvent also cause droplet size to increase. In preferred embodiments of the invention, the range of propellant compositions, as shown in Table 3, may be from 100%) propellant and 0% solvent to 85% propellant and 15 %> solvent. Within this range of percentages, pharmaceutically useful concentrations of Δ^9 THC can be achieved and droplet size is still small enough (<5.8μm) to provide excellent aerosol delivery of the drug. While these ratios reflect preferred embodiments of the invention, it will be recognized by those of skill in the art that the exact ratio of propellant to solvent (e.g. ethanol) may vary according to the desired final concentration of Δ^9 THC and droplet size. Any ratio of propellant to solvent that results in appropriate sized droplets and adequate dissolution of the Δ^9 THC may be used in the practice of this invention, and this will generally be in the range of from 100 to 80% propellant and 0 to 20%) solvent. It is expected that a wide variety of solvents, such as ethanol, propanol, propylene glycol, glycerol, polyethylene glycol, etc. may be used in the preparation of formulations contemplated by this invention.

Those skilled in the art will also recognize that the "respirable dose" (or mass of Δ^9 THC in particles with aerodynamic diameters small enough to be delivered to and absorbed by the lungs) (Figure 1) may be increased by choosing MDI spray nozzles of different design and smaller orifice diameters. Respirable doses may also be increased by extending the mouthpiece of the MDI in such a way as to create an integral or separate aerosol spacer or reservoir attached to the mouthpiece of the MDI. This promotes an increase in droplet evaporation and hence in the percentage of the dose in smaller "respirable" particles or droplets. Generally, the optimal size of a respirable droplet is less than 10μm in size.

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

TABLE 3. Apparent Solubility of Δ⁹ THC in Ethanol/HFA Propellant Blends				
Formulation	**Mass (g) of Δ⁹ THC in Sample**	**Mass (g) of Formulation Sampled**	**Apparent Solubility Mean (±SD)**	**Comments**
Δ⁹ THC in 100% HFA 134a	0.000240	0.1071	0.224% w/w (±0.063)	Excess Δ⁹ THC added to propellant blend (in pressurized MDI). Solubility sample removed using puff absorber. n=5
Δ⁹ THC in 5% Ethanol / 95% HFA 134a	0.00144	0.0914	1.585% w/w (±0.321)	As above
Δ⁹ THC in 10% Ethanol / 90% HFA 134a	0.00363	0.1036	3.511% w/w (±0.249)	As above
Δ⁹ THC in 15% Ethanol / 85% HFA 134a	0.00536	0.1098	4.883% w/w (±0.224)	As above
Δ⁹ THC in 100% HFA 227	0.00021	0.1451	0.147% w/w (±0.008)	As above
Δ⁹ THC in 5% Ethanol / 95% HFA 227	0.00134	0.0979	1.339% w/w (±0.169)	As above
Δ⁹ THC in 10% Ethanol / 90% HFA 227	0.00454	0.1267	3.240% w/w (±0.161)	As above
Δ⁹ THC in 15% Ethanol / 85% HFA 227	0.00623	0.1062	5.940% w/w (±0.191)	As above

A distinct advantage of the present formulations is that, surprisingly, the use of surface active agents or "surfactants" as valve lubricants and solubilizers is not necessary. This is in contrast to the invention of Purewal and Greenleaf (European Patent 0,372,777; reference #25) which provides HFA 134a/ethanol mixtures to produce stable formulations of pharmaceuticals in the presence of lipophilic surface active agents. Lipophilic surface active agents are incorporated in that invention in order to suspend undissolved material and to ensure adequate valve lubrication of the MDI. Without adequate valve lubrication, the useful life of the MDI and its ability to deliver an accurate dose of drug are severely attenuated. However, probably due to the inherent lubricity of the formulations of the present invention, the use of such surface active agents is unnecessary. This simplifies the composition and thus is an advantage with respect to cost and

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

A major consideration in the formulation of any drug is its stability. Δ^9 THC is known to deteriorate upon storage so that the effective concentration decreases and the purity is vitiated. The stability of the formulations of the present invention were tested according to accelerated storage testing protocols. The results are given in Figure 1 and Tables 4 A and 4B. The formulations of the present invention were shown to be stable with respect to the release of aerosolized Δ^9 THC in reproducible doses following accelerated storage testing. Apparently, the containment of Δ^9 THC in solution in the non-aqueous formulations of the present invention is excellent with respect to chemical degradation, making possible the construction of a multidose inhaler with a good shelf life prognosis.

Further, lipophilic materials like Δ^9 THC are generally known to partition into the elastomers of the valves in MDI formulations. (Δ^9 THC is highly lipophilic as reflected in its octanolrwater partition coefficient of 6000:1). Over time, this partitioning results in a decrease in the emitted or delivered dose of a lipophilic drug. Thus, this phemonemon also decreases the useful shelf-life of such preparations. However, the data presented in Figure 1 and Table 4 show that this is not the case with the formulations of the present invention. The emitted or delivered doses were constant over the time period tested. This may be due to the somewhat surprising preference of Δ^9 THC for the formulation itself, rather than for the valve elastomers. TABLE 4A. Formulation and aerosol characteristics of Δ^9 THC pressurized metered dose inhalers in ethanol/hydrofluoroalkane (HFA) propellant blends.

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

Inhaler	Formulation (% w/w)			Description
	Δ⁹ THC	Ethanol	Propellant	
1	0.13%	~5%	95% HFA 134a	3/98 Pale Yellow Solution
2	0.13%	~5%	95% HFA 227	3/98 Pale Yellow Solution
3	0.12%	~5%	95% HFA 134a	3/98 Pale Yellow Solution
4	0.18%	~5%	95% HFA 134a	3/98 Pale Yellow Solution
5	0.27%	~5%	95% HFA 227	3/98 Pale Yellow Solution
6	0.25%	~5%	95% HFA 134a	3/98 Pale Yellow Solution
7	0.57%	~5%	95% HFA 134a	3/98 Yellow Solution
8	0.58%	~5%	95% HFA 227	3/98 Yellow Solution
9	0.49%	~5%	95% HFA 134a	3/98 Yellow Solution
10	1.02%	~5%	95% HFA 134a	3/98 Yellow Solution
11	1.11%	~5%	95% HFA 227	3/98 Yellow Solution
12	0.97%	~5%	95% HFA 134a	3/98 Yellow Solution
SS* #1 Initial	1.07%	4.94%	94.0% HFA 134a	6/98 Yellow Solution
SS* #1 after 28 days at 40°C/82% RH**	1.07%	4.94%	94.0% HFA 134a	7/98 Yellow Solution
SS* #2 after 21 days at 40°C/82% RH**	1.00%	5.01%	95% HFA 134a	7/98 Yellow Solution
SS* #3 Modified Actuator***	1.02%	5.15%	93.8% HFA 134a	10/98 Yellow Solution

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

[a] Mean (Standard Deviation) of five determinations. [b] Mass of Δ^9 THC aerosol particles <5.8 μm aerodynamic diameter
*SS: Stability Sample ** RH: relative humidity

*** Aproximate spray nozzle diameter = 0.2 mm.

TABLE 4B. Formulation and aerosol characteristics of Δ^9 THC pressurized metered dose inhalers in ethanol/hydrofluoroalkane (HFA) propellant blends.

Inhaler	Aerosol Characterization		
	Metered Dose (mg)[a]	Emitted Dose (mg)[a]	Fine Particle Dose (mg)[a,b]
11	1.72 (0.25)	1.32 (0.17)	ND
12	0.94 (0.23)	0.97 (0.10)	0.38 (0.02)
SS* #1 Initial	1.10 (0.07)	0.90 (0.03)	0.22 (0.03)
SS* #1 after 28 days at 40°C/82% RH**	1.06 (0.03)	0.92 (0.04)	0.23 (0.02)
SS* #2 after 21 days at 40°C/82% RH**	1.02 (0.05)	0.90 (0.05)	0.21 (0.02)
SS* #3 Modified Actuator***	ND	ND	0.40 (n=1)

[a] Mean (Standard Deviation) of five determinations. [b] Mass of Δ^9 THC aerosol particles with <5.8 μm aerodynamic diameter *SS: Stability Sample ** RH: relative humidity ND: not determined *** Approximate spray nozzle diameter = 0.2 mm

The final concentration of Δ^9 THC in a given formulation may be varied by adjusting the ratio of propellant to solvent and thus the solubility of the Δ^9 THC. Higher percentages of solvent (e.g. ethanol) generally allow a higher amount of Δ^9 THC to be dissolved. For example, in preferred embodiments of the invention, the apparent solubility of Δ^9 THC ranged from 0.147% w/w to 5.94%> w/w as the propellant composition varied from 100% HFA 227 to 85% HFA 227 and 15% ethanol.

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

Further, as stated above, the "fine particle dose" or "respirable dose" of a drug dispensed with an MDI is a function of the spray nozzle diameter. In Figure 1 and Tables 4A and 4B, the spray nozzle diameter is 0.4mm. The "fine particle dose" or "respirable dose" of the formulations of the present invention was shown to be unaffected by storage.

The Δ^9 THC of the present invention is pharmaceutically pure. That is, its form is the nonionized resinous drug substance (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9- trimethyl-3-pentyl-6H-dibenzo[b,d]-pyran-l-ol. Although its preferred embodiment in this invention is not a salt or ester, it will be readily understood by those of skill in the art that other appropriate forms of Δ^9 THC may be synthesized (e.g. esters and salts) and thus used in the practice of this invention.

The desired final concentration of Δ^9 THC in a patient's serum will vary from patient to patient depending on, for example, the nature and severity of the condition being treated, and the patient's overall condition, weight, gender and response to the drug, etc. But the desired range will generally be 10-100ng/ml at 15 minutes following inhalation. The level of Δ^9 THC in a patient's serum can be readily and reliably monitored by gas chromatography/mass spectrophotometry (GC/MS).

The exact treatment protocol to be used may vary from patient to patient depending on the circumstances. For example, in a preferred embodiment of the invention, a patient receiving chemotherapy may have one dose of Δ^9 THC prescribed via inhalation, to be administered 15 minutes before chemotherapy and 4-8 times daily following chemotherapy. In another preferred embodiment, a patient suffering from anorexia associated with AIDS wasting syndrome may have Δ^9 THC by inhalation prescribed 3-5 times daily, 30 minutes before each meal or snack. In other preferred embodiments, a patient suffering form cancer pain, or spasticity related to either multiple sclerosis or spinal cord injury may have Δ^9 THC by inhalation prescribed 3-6 times daily. Those skilled in the art will readily recognize that the treatment protocol may be crafted so as to address the particular needs of each individual patient on a case by case basis.

Δ^9 THC may be used alone or in combination with other medications. Those skilled in the art will readily recognize that, for example, in the case of AIDS wasting syndrome, the patient will likely also be taking drugs that combat the AIDS virus. Similarly, those skilled in the art will readily recognize that patients receiving chemotherapy for cancer may also receive other antiemetics, and cancer patients seeking to relieve pain are likely to receive opioids as well as nonsteroidal anti-inflammatory agents.

The containers for the formulations of the instant invention may be any that are suitable for the efficacious delivery of aerosol inhalants. Several containers and their method of usage are known to those of skill in the art. For example, MDIs can be used with various dose metering chambers, various plastic actuators and mouthpieces, and various aerosol holding chambers (e.g. spacer and reservoir devices), so that appropriate doses of Δ^9 THC reach and deposit in the lung

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

5,284,133 to Burns and Marshak, which is herein incorporated by reference, can be used to prevent overdose or unauthorized consumption of Δ^9 THC. Figure 2 provides a generalized drawing of an MDI containing the composition of this invention and provides the advantage of delivering metered quantities of Δ^9 THC on a repetitive basis. The MDI includes a container 100 for holding the composition and a valve delivery mechanism 102 for delivery of aerosolized Δ^9 THC.

While the invention has been described in terms of its preferred embodiments, those skilled in the art will recognize that the invention can be practiced with modification within the spirit and scope of the appended claims.

REFERENCES

1. Workshop on the medical utility of marijuana. National Institutes of Health, August 1997.

2. Beal, J.A., Olson, R., Lefkowitz, L., Laubenstein, L., Bellman, P., Yangco, B., Morales, J.O., Murphy, R., Powderly, W., Plasse, T.F., Mosdell, K.W.and Shepard, K.W. (1997) Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J. Pain. Symptom Manage. 14:7-14. 3. Beal, J.A., Olson, R., Laubenstein, L., Morales, J.O., Bellman, B., Yangco, B., Lefkowitz, L., Plasse, T.F. and Shepard, KN. (1995) Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS J. Pain. Symptom Afanage.10:89-97.

4. McCabe, M., Smith, F.P., MacDonald, J.S., Wooley, P.V., Goldberg, D. and Schein, P.S. (1988) Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest. New Drugs 6:243-246.

5. Lucas, V.S. and Laszlo, J. (1980) Δ^9 -THC for refractory vomiting induced by cancer chemotherapy. JAMA 243:1241-1243.

6. Sallan, S.E., Cronin, C, Zelen, M.and Zinberg, N.E. (1980) Antiemetics in patients receiving chemotherapy for cancer: a randomized comparision of Δ^9 THC and prochlorperazine. N. Engl. J. Med. 302:135-138.

7. Frytak, S., Moertel, C.G., O'Fallon, J.R., Rubin, J., Creagan, E.T., O'Connell, M.J., Schutt, A.J. and Schwartau, N.W. (1979) Delta-9-tetrahydrocarmabinol as an antiemetic for patients receiving cancer chemotherapy: a comparison with prochlorperazine and a placebo. Ann. Inter. Med. 91 :825-830.

8. Chang, A.E., Shiling, D.J., Stillman, R.C., Goldgerg, N.H., Seipp, C.A., Barofdky, I., Simon, R.M. and Rosenberg SA (1979) Δ^9 THC as an antiemitic in cancer patients receiving high-dose methotrexate. Ann. Internal. Med. 91:819-824.

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

10. Noyes, J.R., Brunk, S.F., Baram, D.A. and Canter, A. (1975) The analgesic properties of Δ^9 THC and codeine. J. Clin. Pharmacol. 15:139-143.

11. Noyes, R., Jr., Brunk, S.F., Baram, D.A. and Canter, A. (1975) Analgesic effect of Δ^9 -tetrahydrocannabinol. J. Clin. Pharmacol. 15:139-143.

12. Brenneisen, R., Egli, A., Elosohlly, M.A., Henn, V. and Spiess, Y. (1996) The effect of orally and rectally administered Δ^9 THC on spasticity: a pilot study with 2 patients. Int. J. Clin. J. Pharmocol. Ther. 34:446-452.

13. Ungerleider, J.T., Andyrsiak, T.F.L., Ellison, G.W. and Myers, L.W. (1987) Δ^9 THC in the treatment of spasticity associated with multiple sclerosis. Adv. Alcohol Subst. Abuse 7:39-50.

14. Clifford, D.B. (1983) Tetrahydrocannabinol for tremor in multiple sclerosis. Ann. Neurol. 13:669-171.

15. Petro, D.J. and Ellenberger, C. (1981) Treatment of human spasticity with delta 9 -tetrahydrocannabinol. J. Clin. Pharmacol. 2 413S-416S.

16. Maurer, M., Henn, V., Dittrich, A. and Hofman, A. (1990) Delta 9- tetrahydrocannabinol shows antispastic and analgesic effects in a single case double- blind trial. Eur. Arch. Psychiatry Neurol. Sci. 240:1-4.

17. Merritt, J., Crawford, W., Alexander, P., Anduze, A. and Gelbart, S. (1980) Effects of marihuana on intra ocular and blood pressure in glaucoma. Opht. 87:222- 228.

18. Cooler, P. and Gregg, J.M. (1977) Effect of delta 9-Δ^9 THC on intra ocular pressure in humans. South. Med. J. 70:951-954. 19. PDR (1995) Physician's Desk Reference (49) Montvalek, New Jersey: Medical Economics Data Production Co., pp.2787.

20. Ohlsson, A., Lindgren, J.E., Wahlen, A., Agurall, S., Hollister, L.E. and Gillespie, H.K. (1980) Plasma Δ^9 THC concentrations and effects after oral and intravenous administration and smoking. Clin. Pharmacol. Ther. 28:409-416.

21. Olsen, J.L., Lodge, J.W., Shapiro, B.J. and Tashkin, D.P. (1976) An inhalation aerosol of Δ^9- tetrahydrocannabinol. J Pharmacy and Pharmacol. 28:86.

22. Dalby, R.N. and Byron, P.R. (1988) Comparison of output particle size distributions from pressurized aerosols formulated as solutions or suspensions. Pharm. Res. 5:36-39.

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

23. Tashkin, D.P., Reiss, S., Shapiro, B.J., Calvarese, B., Olsen, J.L. and Lidgek, J.W. (1977) Bronchial effects of aerosolized Δ^9- tetrahydrocannabinol in healthy and asthmatic subjects. Amer. Rev. of Resp. Disease. 115:57-65.

24. Williams, S.J., Hartley, J.P.R. and Graham, J.D.P. (1976) Bronchodilator effect of delta-9-THC administered by aerosol to asthmatic patients. Thorax. 31 :720-723.

25. European Patent 0, 12,111 (Riker Laboratories). Medicinal aerosol formulations.

PATENTZITATE

Zitiertes Patent	Eingetragen	Veröffentlichungsdatum	Antragsteller	Titel
US4635651 *	29. Aug. 1980	13. Jan. 1987	Jacobs Allen W	Process for the inclusion of a solid particulate component into aerosol formulations of inhalable nicotine
US5502076 *	8. März 1994	26. März 1996	Hoffmann-La Roche Inc.	Dispersing agents for use with hydrofluoroalkane propellants
US5804592 *	30. Mai 1997	8. Sept. 1998	Unimed Pharmaceuticals, Inc.	Method for improving disturbed behavior and elevating mood in humans

* Vom Prüfer zitiert

NICHTPATENTZITATE

Referenz
1 * See also references of EP1124551A2

* Vom Prüfer zitiert

REFERENZIERT VON

Zitiert von Patent	Eingetragen	Veröffentlichungsdatum	Antragsteller	Titel
WO2001013886A1 *	15. Aug. 2000	1. März 2001	Roxane Laboratories, Inc.	Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent
WO2001064212A1 *	28. Febr. 2001	7. Sept. 2001	University College London	Modulators of the endocannabinoid uptake and of the vallinoid receptors
WO2001066089A2 *	9. März 2001	13. Sept. 2001	Gw Pharma Limited	Pharmaceutical compositions comprising cannabis
WO2001066089A3 *	9. März 2001	21. Febr. 2002	Gw Pharma Ltd	Pharmaceutical compositions comprising cannabis
WO2003006010A1 *	10. Juli 2002	23. Jan. 2003	Norton Healthcare Limited	Aerosol formulations of δ8 tetrahydrocannabinol

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

Zitiert von Patent	Eingetragen	Veröffentlichungsdatum	Antragsteller	Titel
WO2003070753A1 *	14. Febr. 2003	28. Aug. 2003	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Method for producing a powder inhalant containing a salt of the cgrp antagonist bibn4096
WO2007002186A1 *	20. Juni 2006	4. Jan. 2007	Unimed Pharmaceuticals, Inc.	Dronabinol treatment for migraines
EP1881757A2 *	15. Mai 2006	30. Jan. 2008	Unimed Pharmaceuticals, Inc.	Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
EP1881757A4 *	15. Mai 2006	10. Sept. 2008	Unimed Pharmaceuticals Inc	Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
US6747058	15. Aug. 2000	8. Juni 2004	Unimed Pharmaceuticals, Inc.	Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor
US6900317	12. Febr. 2003	31. Mai 2005	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
US7648696	5. Sept. 2003	19. Jan. 2010	Unimed Pharmaceuticals, Llc	Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent
US7905230	10. Dez. 2003	15. März 2011	Novartis Ag	Metered dose inhaler with lockout
US8079360	14. Febr. 2008	20. Dez. 2011	Canon Kabushiki Kaisha	Inhaler
US8082917	23. Okt. 2008	27. Dez. 2011	Canon Kabushiki Kaisha	Inhaler
US8481091	10. Sept. 2012	9. Juli 2013	Gw Pharma Limited	Pharmaceutical compositions
US8512767	7. Sept. 2012	20. Aug. 2013	Gw Pharma Limited	Pharmaceutical compositions
US9717683	29. Juni 2016	1. Aug. 2017	Ep Pharma, Llc	Low-temperature inhalation administration of cannabinoid entities

* Vom Prüfer zitiert

KLASSIFIZIERUNGEN

Internationale Klassifikation	A61K9/00, A61P25/06, A61M15/00, A61K31/352, A61P25/04, A61M13/00, A61K47/06, A61P43/00, A61P1/14, A61P1/08, A61K9/12, A61P21/02
Unternehmensklassifikation	A61K9/008, A61K31/352
Europäische Klassifikation	A61K9/00M20B6, A61K31/352

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

Datum	Code	Ereignis	Beschreibung
4. Mai 2000	AL	Designated countries for regional patents	**Kind code of ref document:** A2 **Designated state(s):** GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
4. Mai 2000	AK	Designated states	**Kind code of ref document:** A2 **Designated state(s):** AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
28. Juni 2000	121	Ep: the epo has been informed by wipo that ep was designated in this application	
13. Juli 2000	DFPE	Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)	
24. Aug. 2000	AK	Designated states	**Kind code of ref document:** A3 **Designated state(s):** AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
24. Aug. 2000	AL	Designated countries for regional patents	**Kind code of ref document:** A3 **Designated state(s):** GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
20. März 2001	WWE	Wipo information: entry into national phase	**Ref document number:** 21430/00 **Country of ref document:** AU
9. Apr. 2001	WWE	Wipo information: entry into national phase	**Ref document number:** 1020017004513 **Country of ref document:** KR
25. Apr. 2001	ENP	Entry into the national phase in:	**Ref country code:** JP **Ref document number:** 2000 577974 **Kind code of ref document:** A **Format of ref document f/p:** F
26. Apr. 2001	WWE	Wipo information: entry into national phase	**Ref document number:** PA/a/2001/004188 **Country of ref document:** MX

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.

Datum	Code	Ereignis	Beschreibung
25. Mai 2001	WWE	Wipo information: entry into national phase	**Ref document number:** 1999965726 **Country of ref document:** EP
9. Aug. 2001	WWP	Wipo information: published in national office	**Ref document number:** 1020017004513 **Country of ref document:** KR
22. Aug. 2001	WWP	Wipo information: published in national office	**Ref document number:** 1999965726 **Country of ref document:** EP
30. Aug. 2001	REG	Reference to national code	**Ref country code:** DE **Ref legal event code:** 8642
22. Nov. 2001	ENP	Entry into the national phase in:	**Ref country code:** CA **Ref document number:** 2344637 **Kind code of ref document:** A **Format of ref document f/p:** F **Ref document number:** 2344637 **Country of ref document:** CA
20. Nov. 2003	WWG	Wipo information: grant in national office	**Ref document number:** 21430/00 **Country of ref document:** AU
7. Sept. 2006	WWG	Wipo information: grant in national office	**Ref document number:** 1020017004513 **Country of ref document:** KR

Google-Startseite - Sitemap - USPTO-Bulk-Downloads - Datenschutzerklärung - Nutzungsbedingungen - Über Google Patentsuche - Feedback geben

Daten bereitgestellt von IFI CLAIMS Patent Services.

Try the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.